1 Maternal obesity shapes the B lymphocyte and antibody repertoires of

2 human colostrum

- 3
- 4 Erick Sánchez-Salguero¹, Diana Bonilla-Ruelas¹, Mario René Alcorta-García^{2,4},
- 5 Víctor Javier Lara-Diaz^{3,6}, Claudia Nohemí López-Villaseñor^{2,4}, Marion E G
- 6 Brunck^{1,5*}
- ⁷ ¹ The Institute for Obesity Research, Tecnologico de Monterrey, Av. Eugenio Garza Sada
- 8 2501 Sur, Tecnológico, 64700, Monterrey, Nuevo León, México.
- 9 ² Hospital Regional Materno Infantil, Servicios de Salud de Nuevo León, OPD, Av. San
- 10 Rafael 460, San Rafael, 67140 Guadalupe, Nuevo León, México.
- ³ Pediatras404, San Pedro Garza Garcia, Nuevo León, México.
- ⁴ School of Medicine and Health Sciences, Tecnologico de Monterrey, Av. Eugenio Garza
- 13 Sada 2501 Sur, Tecnológico, 64849, Monterrey, Nuevo León, México.
- ⁵ School of Engineering and Sciences, Tecnologico de Monterrey, Av. Eugenio Garza
- 15 Sada 2501 Sur, Tecnológico, 64849, Monterrey, Nuevo León, México.
- ⁶ University of New South Wales, Faculty of Medicine, Sydney, Australia.
- 17
- 18
- 19 Correspondence to: <u>marion.brunck@tec.mx</u>
- 20

21 ABSTRACT

22

The prevalence of obesity is rapidly increasing worldwide and its impact on future 23 generations must be assessed. We recently showed that colostrum from mothers 24 with obesity contained a significantly reduced B lymphocytes (CD19⁺) fraction. 25 Here, in a subsequent transversal cohort study of 48 mothers, we exhaustively 26 characterize the B lymphocytes subsets present in peripheral blood and colostrum 27 from obese mothers and describe a pervasive alteration of the B lymphocytes 28 compartment of human colostrum accompanied by a dysregulated antibody 29 composition. We describe significant decreases in regulatory B cells and soluble 30 IgA concentrations, combined with increases in soluble IgG and double negative 2 31 (CD19⁺, CD27⁻, IqD⁻, CD38⁻, CD24⁻, CD21⁻, CD11c⁺) B lymphocytes. These 32

alterations correlated with maternal BMI and corporal fat %. We provide evidence for possibly autoimmune IgG present in obese colostrum, and for the proinflammatory consequences of obese colostrum in vitro. Beyond the impact of obesity, we evidence the selective presence of B lymphocyte subtypes in colostrum and in situ production of IgG antibodies, which expands our current understanding of the origin of colostrum IgG. As maternal milk antibodies play a crucial role in regulating neonatal gut immune development, this work uncovers maternal obesity as a potential risk factor for compromised breastmilk immune components, calling for more research on the long-term health of lactating infants. KEYWORDS: Colostrum, Obesity, B lymphocytes, IgG, IgA

58 1. INTRODUCTION

59

Tolerizing responses in the gut allow the establishment of the microbiota and 60 efficient food digestion, contributing to health. Disruptions in these tolerizing 61 responses cause inflammation that promote disease. For example, in ulcerative 62 colitis, immune tolerance to commensal microbes is impaired¹. This prevents the 63 expansion of a tolerizing RORy⁺ Treg population, fueling gut inflammation that 64 primes the disease². Interestingly, $RORy^{+}$ Treg populations essential to the 65 establishment of the microbiota are transmitted exclusively through breastmilk and 66 persist through adulthood³. Therefore, essential immune responses in the adult gut 67 68 are imprinted at least in part during breastfeeding and inappropriate responses prime adverse conditions later in life⁴. 69

70

71 Maternal obesity is a rising condition worldwide that correlates with variations in 72 multiples breastmilk components including the microbiota, Human-milk oligosaccharides (HMO) and lipids⁵⁻⁸. However, reports on immune bioactives like 73 cytokines and leukocytes remain scarce⁹⁻¹². We recently evidenced a significant 74 reduction of the B lymphocytes compartment in the colostrum of mothers with 75 obesity¹³. Here, we further characterize 18 B lymphocytes subpopulations in obese 76 colostrum and describe pervasive alterations of the resolved populations, including 77 78 less B_{red}-like and more of a recently described pro-inflammatory B lymphocyte population, also known as double-negative 2 (DN2) B cells^{14,15}. These alterations 79 at the cellular level are accompanied by significant regulations in colostrum 80 antibodies, including less soluble IgA (sIgA), and more soluble IgG (sIgG). 81 slgG 82 Interestingly, obese colostrum had increased recognition of Nacetylglucosamine (GlcNAc) which is present on bacterial and fungal cell walls, but 83 also composes various human tissues, hinting toward a possible transfer of 84 autoimmunity^{16–18}. Finally, we show that in contrast to colostrum from "lean" 85 mothers, obese colostrum leads to activation of human macrophages in vitro. 86 Overall, we describe here that maternal obesity regulates B lymphocytes subsets 87

88 and antibodies in human colostrum, with possible long-lasting impact on the 89 suckling neonate's health.

90

91 2. MATERIALS AND METHODS

92

93 2.1 Human samples

94 This cross-sectional study was approved by the Ethics Committee of the Hospital Regional Materno Infantil, Servicios de Salud de Nuevo León, and by the IRB at 95 the School of Medicine and Health Sciences, TecSalud, in Monterrey, Mexico 96 (CarlMicrobio2018, Reg. No. DEISC-19 01 18 09). Eligible women attending the 97 98 hospital for delivery were recruited between September 2022 and April 2023. Participation in the study was based on the following inclusion criteria: (1) maternal 99 100 age between 18 and 34 years, (2) over 5 prenatal visits without any adverse event during pregnancy, (3) pre-pregnancy BMI >18.5 and <25, or >30, (4) term infant, 101 102 and (5) willingness to participate. Exclusion criteria included (1) having received antibiotics anytime during the 3-month period before birth, or having received a 103 104 prolonged antibiotic treatment (>3 months) anytime during pregnancy, (2) having received immunosuppressive doses of steroids during pregnancy, (3) history of any 105 106 monoclonal antibody treatment, (4) history of chronic disease (outside of obesity), (5) suffering from any nutrition-related disease or dietary restrictions, (6) episodes 107 108 of diarrhea during the last 2 weeks of pregnancy, (7) history of surgery within 12 months prior to pregnancy, (8) history of antineoplastic treatment. Elimination 109 criteria included (1) having received antibiotics for >24 h post-birth, (2) newborn 110 admission to NICU, (3) any additional cause impeding sample collection. Oxytocin 111 was not used during labor. Pre-pregnancy weight was recalled, current height was 112 measured and current body fat percentage (BF%) obtained by impedance at the 113 time of recruitment. Additional variables collected or measured in this work 114 included maternal age, primiparity, infant gender, gestational age at birth, mode of 115 delivery, weight of infant at birth, volume of colostrum obtained, frequency of B 116 lymphocytes subpopulations in blood and colostrum samples, type and 117 concentrations of antibodies and frequency of antibody-producing cells in 118

colostrum. Additional details are included in the study's STROBE statement 119 (Supplementary Table 1). Participants were allocated to the "obese" (BMI>30, 120 BF%>30) or "lean" (18.5>BMI<25, BF%<22) groups according to the WHO 121 guidelines. Upon recruitment and signed informed consent, 4 ml of maternal 122 peripheral blood were drawn into K₂EDTA coated tubes (BD Vacutainer®, cat. 123 366643). The same day, after infant feeding, the nipple area of the breast was 124 125 gently cleaned with neutral soap and water, and 1-3 ml of colostrum were collected using a manual pump. Samples were immediately stored on ice until processing 126 127 and all samples were processed within 2 h of collection.

128

129 **2.2 Isolation of PBMC from peripheral blood**

Ficoll-Paque (Fisher scientific, cat. 17-1440-03) was used to enrich PBMC from peripheral blood and residual erythrocytes were lysed using Pharm Lyse Solution (BD, cat. 555899), as per manufacturer's instructions. Cells were manually counted using a Neubauer chamber, using 0.4% Trypan blue to discriminate dead cells). Three million live PBMC were then stained for flow cytometry in a total volume of 100 µl.

136

137 **2.3 Cell enrichment from colostrum**

Approximately 2 ml of colostrum were processed for cell enrichment prior to
staining for flow cytometry, as previously reported^{13,19}. Briefly, colostrum volumes
were recorded, and samples were centrifuged at 400 rcf for 15 min at 4°C.
Supernatant were stored away, and cell pellet were washed twice with PBS/1%
FBS/2mM EDTA. Cells were manually counted using a Neubauer chamber using
0.4% Trypan blue to discriminate dead cells. Two million live cells were then
stained for flow cytometry in a total volume of 100 µl.

145

146 **2.4 Flow cytometry**

The same conjugated monoclonal antibodies were used to stain both tissue types,
and antibody and viability stains were titrated independently for each tissue. PBMC
were staining with 1.38 µl of CD19-PerCP Cy5.5 (BioLegend, catalog number)

302230), 5 µl of CD21-PE/DazzleTM 594 (BioLegend, catalog number 354922), 5 150 µl of CD24-Brilliant Violet 786TM (BioLegend, catalog number 311142), 2 µl of 151 CD27-APC (BioLegend, catalog number 302810), 2.5 µl of CD38-Alexa Fluor® 700 152 (BioLegend, catalog number 397206), 2 µl of IgA-VioGreen (Miltenyi Biotec, 153 catalog number 130-113-481), 3 µl of IgG APC Cv7 (BioLegend, catalog number 154 410732), 3 µl of IgD-VioBlue (Miltenyi Biotec, catalog number 130-123-258), and 5 155 µl of CD11c-Brilliant Violet 605TM (BioLegend, catalog number 744436), and 1 µl 156 of Zombie Green (BioLegend, catalog number 423111); in a final volume of 100 µl 157 of PBS/1% FBS/2mM EDTA. As previous publications suggested we optimized 158 staining times for optimal resolution, and incubated 90 min at 4°C in the dark²⁰. 159

For colostrum cells, 2x10⁶ cells were stained using a cocktail including 1.38 µl 160 CD19-PerCP Cy5.5, 5 µl CD21-PE/DazzleTM 594, 5 µl CD24-Brilliant Violet 161 786TM, 2 µl CD27-APC, 3 µl CD38-Alexa Fluor® 700, 5 µl IgA-VioGreen, 5 µl IgG-162 APC Cy7, 5 µl IgD-VioBlue, 5 µl IgG-APC Cy7, and 5 µl CD11c-Brilliant Violet 163 164 605TM; in a final volume of 100 µl of PBS/1% FBS/2mM EDTA. After incubation, samples were washed and resuspended in PBS/1% FBS/2mM EDTA for 165 166 immediate acquisition on a BD® FACSCelesta flow cytometer fitted with 405 nm. 488 nm, and 633 nm lasers and operated through the BD® FACSDiva software 167 168 v.8. Compensation controls were used at each acquisition using compensation beads following manufacturer's recommendations, and automatic compensation 169 was performed prior to acquisition. Over 10⁶ events were recorded from each 170 sample, with the FSC threshold adjusted to 50,000 or 5,000 for blood and 171 172 colostrum, respectively. Analysis was performed using FlowJo X 10.0.7r2. The gating strategy initially optimized was based on previous reports and CD45 stained 173 samples but FMO controls were used to adjust gates for both sample types^{21,22}. 174 The gating strategy is described in Supplementary Fig. 1. 175

176

177 **2.5 IgM, sigA and sigG ELISA**

Flat-bottom 96-well polystyrene plates were coated with 1:5000 PBS-diluted mouse anti-human monoclonal antibody for either IgM (Abcam, cat. ab200541), IgA (Abcam, cat. ab7400b) or IgG (Abcam, cat. ab72528), and incubated 12 h at 4 °C.

After blocking, dilutions of plasma or colostrum supernatants were incubated for 2 181 h at 37 °C. For detection, anti-human IgG, IgA, and IgM coupled to HRP (Abcam, 182 cat. ab102420) were added at 1:8000 dilution and incubated for 1 h at 37 °C. Fifty 183 µl/ well of TMB (Abcam, cat. ab171523) were then incubated 2 min. The reaction 184 was stopped with 50 µl of 0.2 M H_2SO_4 , and plates were read at 450 nm on a 185 spectrophotometer (Tecan's Magellan® universal reader). Quantitative standard 186 187 curves were obtained for each isotype using serial dilutions from recombinant human IgA (Abcam, cat. ab91025), IgG (Abcam, cat. Ab91102) or IgM (Abcam, 188 189 cat. Ab91117).

190

191 **2.6 IgM, IgG, and IgA-secreting cells ELISPOT**

Briefly, 96-well plates were covered with PVDF membranes. After methanol 192 193 activation, membranes were coated with a 1:2500 dilution of mouse anti-human monoclonal antibody recognizing IgM, IgA, or IgG (Abcam, cats. ab200541, 194 195 ab7400, ab72528, respectively). The plates were incubated for 12 h at 4° C, then blocked for 90 min at 25 °C. Colostrum-enriched cells or blood PBMC were seeded 196 197 at 200,000 cells/well in RPMI 1640 with 10% FBS and 100 U/ml penicillin, 0.1 mg/ml streptomycin. Plates were incubated for 18 h at 37 °C and 5% of CO₂. For 198 199 detection, a 1:10,000 dilution of HRP-conjugated goat anti-human IgG, IgA, and IgM (Abcam, cat. ab102420) was incubated 1 h at 37°C. Finally, 50 µl/well 3,3'-200 201 DAB (Sigma-Aldrich, cat. D4418) were added. Membranes were then washed and dried, and pictures were acquired with a Stereoscopic Microscope (Nikon, cat. 202 203 SMZ1500). Spots were counted using the Analyze Particles command in ImageJ (Java®). 204

205

206 **2.7 Colostrum-mediated macrophage cytokine production**

To produce human macrophage-like cells, U937 cells (ATCC, CRL-1593.2) were differentiated over 24 h using 10 ng/ml PMA (Sigma-Aldrich®, cat. 79346) in RPMI 1640, supplemented as above. After 24 h, the media was replaced without PMA but including 2.5% 0.22 µm-filtered colostrum supernatant. After a further 24 h, cells were washed, fresh media without colostrum was added. To quantify

212 cytokines, 5 µL of culture supernatants were obtained every 2 h for a total of 16 h. Samples were centrifuged and stored at -20 °C until quantification. Cytokines were 213 214 quantified using a LEGENDplex kit (BioLegend, cat. 740808) according to the manufacturer's instructions. All samples were immediately read on a BD® 215 FACSCelesta flow cytometer fitted with 405 nm, 488 nm, and 633 nm lasers and 216 operated through the BD® FACSDiva software version 8. Analysis and quantitative 217 218 data were obtain using the FCAP Array software v 3.0 SoftFlow® LEGENDplex[™] Cloud-based Data Analysis Software online²³. 219

220

221 2. 8 Statistical Analysis

Shapiro-Wilk normality tests were performed on each B lymphocyte subtype dataset. Non-normal datasets were compared using Mann-Whitney or one-way Kruskal-Wallis test when comparing >2 groups. Means of normally distributed data were compared using Student's t test. Correlations were investigated using Pearson rank or Spearman r. All these tests were performed in GraphPad Prism v.8 (GraphPad Software Inc®, San Diego CA, USA). Median (IQR) were compared using Independent-Samples Median test in SPSS v.26.

229

230 3. RESULTS AND DISCUSSION

231

3.1 B lymphocytes subpopulations are selectively present in colostrum

We recruited a total of 48 mothers to participate in this study. As per study design, the BMI and BF% of the cohort of mothers with obesity were significantly larger compared to the cohort of "lean" mothers, while no difference were observed in possible confounders such as maternal age, infant gender, gestational age, or delivery type between the groups (Table 1).

We applied an optimized 10-colour flow cytometry panel to detect 18 subpopulations of B lymphocytes in peripheral blood and colostrum. The gating strategy was based on classical and more recent markers used to subtype peripheral blood B lymphocytes (Table 2). We found a reduced fraction of the total B lymphocytes population in obese colostrum compared to the lean cohort

(Supplementary Fig. 2), consistent with previous findings¹³. The reduction was not
 resumed in peripheral blood, suggesting that obesity regulates this compartment
 locally, with observed changes in colostrum.

246

In peripheral blood, we could detect all targeted subpopulations including rare 247 subtypes like B_{rea}-like and transitional B cells (Supplementary Fig. 3) with 248 proportions consistent with previous reports^{22,24-26}. In contrast, in colostrum 249 multiple subtypes could not be detected, notably the early stages of B cell 250 251 ontogeny including transitional and naïve B cells (Fig. 1A). In comparing B lymphocyte subtypes between blood and colostrum, we considered relative 252 proportions (Supplementary Fig. 3), but also concentrations in original samples 253 (Fig. 1) calculated from measured sample volumes, manual cell counts and % 254 255 populations, to account for discrepancies in cellularity between blood and colostrum (Fig. 1). Differences were consistent between population % and 256 257 concentrations. While early ontogeny B cells were absent from colostrum, differentiated subtypes were very significantly increased in this tissue, including 258 B_{reg}-like, DN2-like and plasma-like cells that were rare in peripheral blood (Fig. 1B), 259 although definitive labelling should be based on functional assays such as cytokine 260 261 and antibody production. While switched memory (SwM) B cells were present in similar concentrations in both colostrum and blood, unswitched memory B cells 262 263 (USwM) were significantly underrepresented in colostrum compared to peripheral blood (Fig. 1C). Overall, the results describe pervasive, significant differences in % 264 265 and concentrations of B lymphocytes subtypes between blood and colostrum. This may suggest a selective migration to the mammary acini and colostrum. It further 266 describes human colostrum as containing multiple subpopulations of differentiated 267 B cells, enriching the current state-of-the art^{27,28}. 268

269

We then asked if proportions of specific B cell subpopulations in colostrum were regulated with maternal obesity. In this context, we measured significantly less USwM B cells without detected changes in the SwM B cells (Fig. 1C). While this work is the first to report changes in breastmilk memory B cells in relation with

maternal obesity, others have measured increased breastmilk SwM B cells from HIV-infected mothers²⁸. Increased SwM B cells were also found in mouse visceral adipose tissue²⁹. IgG isotype switching follows stimulation with cytokines that are increased in obesity^{29,30}. We propose that the increase in SwM B cells depletes USwM, causing the significant decrease in colostrum USwM B cells. In support of this, obesity peripheral blood indeed contained significantly less USwM and significantly more SwM B lymphocytes (data not shown).

281

3.2 Obesity colostrum harbors a dysregulated B lymphocyte repertoire, hinting towards an inflammatory profile

Looking at functional populations, we found a significantly reduced B_{reg}-like cell 284 fraction in the colostrum of mothers with obesity (Fig. 2A). The relative abundance 285 of colostrum B_{req}-like cells negatively correlated with maternal pre-pregnancy BMI 286 and current BF%. Inflammation has been linked to decreased Breg-like cells 287 functions and growth^{31,32}. Obesity is now accepted as a state of chronic 288 inflammation, which supports the physiological interpretation of the results^{33,34}. B_{rea} 289 290 cells limit ongoing immune reactions, restore immune homeostasis, and promote tolerance to commensals of the gut microbiota, suggesting consequences of this 291 reduction for the infant's pioneering microbiota^{35–38}. We then investigated DN2-like 292 B cells, recently described in blood in multiple inflammatory scenarios including 293 autoimmune disorders, acute infections and obesity^{22,15,39}. Consistent with the 294 inflammatory state suggested by a reduced B_{rea}-like B cell fraction, we found 295 296 significantly increased proportions of DN2-like cells, and these changes positively correlated with pre-pregnancy BMI and current BF% (Fig. 2B). While the exact 297 origins and roles of DN2-like cells remain unclear to date, their occurrence follow a 298 proinflammatory stimulus^{40–43}. Future experiments could include measuring the 299 300 transcription factor T-bet and IFNy production from these cells to confirm cell identity^{44–46}. We then investigated plasma-like cells that could be producing 301 antibodies. These were increased in obesity colostrum, and as observed with DN2-302 like B cells, colostrum plasma-like cell proportions positively correlated with pre-303 pregnancy BMI and with current BF% (Fig. 2C). Plasma cells can differentiate 304

following IFN γ^{47} and leptin signaling⁴⁸. These soluble factors are increased in obesity⁴⁹, which provides a physiological explanation for our findings.

307

Correlation values (r²) for the 3 cell types were consistently higher for BF% compared to BMI. Despite the historical use of BMI as an indicator of obesity, the lack of precision in the composition of the measured weight is confounding. Our results suggest a clearer association between increased BF% and the regulation of specific B cell subtypes in human colostrum.

313

314 3.3 Obesity modulates colostrum plasma like-cells and their antibody 315 secreting function

Having identified a significant increase in colostrum plasma-like B cells, we 316 wondered if this population exhibited changes in their antibody production, 317 isotypes, and antigen specificity. As B cells gradually lose CD19 surface 318 319 expression during differentiation towards antibody-secreting cells, we measured CD19 MFI within the plasma-like cell subpopulations in both groups to compare 320 their relative degree of maturity⁵⁰. We identified 3 discrete subpopulations based 321 on CD19 expression level, with a significant increase in the CD19^{low} plasma-like B 322 cell fraction in the obese cohort (Supplementary Fig. 4)⁵¹. This suggests obese 323 colostrum is enriched in plasma-like cells maturing towards antibody-secreting 324 325 cells, possibly driven by proinflammatory signals linked to obesity as described earlier^{47,48}. 326

327

We compared isotypes of the plasma-like cells and evidenced a significantly 328 increased fraction of IgG⁺ plasma-like cells in obese colostrum, while the IgA⁺ 329 fraction remained unchanged (Fig. 3A). Interestingly, intra-individual correlations of 330 331 IgA⁺- and IgG⁺-plasma-like cells exhibited a trend whereby obese colostrum contained a switched relation of both isotypes (Fig. 3B), suggesting a 332 compensatory mechanism although more work is required to mechanistically 333 explain this. We then investigated if there were more antibody-secreting cells in 334 obese colostrum. Using an ELISPOT assay, we found a significant increase in IgG-335

secreting cells in obese colostrum which positively correlated with maternal BMI 336 337 and BF% (Fig. 3C). While IgA-secreting cell concentrations remained unchanged, we observed a negative correlation between their concentration, and maternal BMI 338 and BF%. These results confirm colostrum contains B cell subsets that actively 339 produce antibodies in situ, adding to the current understanding of breastmilk IgG 340 originating from FcN-mediated transcellular translocation⁵². We measured 341 significantly more slgG and less slgA concentrations in obese colostrum (Fig. 3D). 342 These changes may affect the establishment of the intestinal microbiota⁵³. 343 Dysregulations in maternal antibodies received through breastmilk also impact the 344 growth and maturation of the neonatal intestine⁵⁴. These results confirm previous 345 reports of increased local concentrations of IgG in obesity⁵⁵. We further wondered 346 if the increased IgG may be autoimmune, as accumulating evidence links obesity 347 to autoimmune disorders⁵⁶. We measured the concentration of colostrum IgG 348 specifically recognizing N-acetylglucosamine (GlcNAc), a common bacterial and 349 fungal antigen that bears similarities with circulating hyaluronic acid in obesity^{57,58}. 350 We found a very significant increase of anti-GlcNAc IgG in obese colostrum (Fig. 351 3D). The GlcNAc used as target antigen in the assay was obtained from Group A 352 Streptococcus pyogenes (GAS), however the incidence GAS infection is low 353 among pregnant mothers from low income countries like Mexico⁵⁹, and no 354 participant reported GAS infection during pregnancy. These results then suggest 355 356 autoreactive anti-GlcNAc IgG in obese colostrum, and it will be important to investigate how this affects neonatal gut health. 357

358

359 3.4 Obese colostrum IgG may originate from proinflammatory DN2 B 360 lymphocytes

We then wondered what cells could produce IgG in obese colostrum. We noticed DN2-like cells were almost entirely IgG⁺ (Fig. 4A), and these cells have been reported to secrete IgG⁴⁰. Since obese colostrum contained significantly more IgG⁺ DN2-like and IgG⁺ plasma-like cells, together with more sIgG (Fig. 3C) and IgGsecreting cells (Fig. 3A), we correlated IgG concentrations with these possible local producers. There were clear correlations between IgG colostrum concentrations

and both IgG⁺ cell types in obesity but not in the lean cohort (Fig. 4B, gray and red data, respectively). Looking at IgG-producing cells, the only significant correlation was with the proportion of DN2-like cells, in obese colostrum only (Fig. 4C, gray data), suggesting these cells participate in the production of IgG in this context. As DN2 cells are mostly found in a proinflammatory setting^{15,40,60}, it will be relevant to investigate the IgG subtypes produced and their consequence *in vivo*.

373

374 **3.5 Obese colostrum activates human macrophages** *in vitro*

We finally investigated the effect of obese colostrum on human macrophages. 375 Macrophages reside in the neonatal intestine and regulate the local inflammatory 376 response during the first days of life⁶¹. Co-cultures evidenced that colostrum from 377 mothers with obesity prompted TNF- α production while colostrum from lean 378 379 mothers did not (Fig. 5A). Until shortly after birth, the neonatal intestine contains macrophages replenished by blood monocytes due to commensal stimulation. In 380 381 health, these intestinal macrophages show low pro-inflammatory responses, including minimal IL-6 and TNF- α expression^{62–66}. Elevated TNF- α levels in the 382 neonatal intestine increases NEC pathogenesis⁶⁷. On the other hand, while IL-6 383 was significantly increased by obese colostrum stimulation, this cytokine was 384 385 already present in basal conditions (Fig. 5B). Overall, there was a direct induction of inflammation of macrophages by obese colostrum. Further research should 386 investigate activation mechanisms and long-term consequences for neonatal 387 health. 388

389

390 **4. Conclusions**

This is the first report of obesity-mediated regulation of B lymphocytes and antibodies in human colostrum. We measured notable changes in phenotypically and functionally distinct B lymphocyte subpopulations, which in turn adversely affect the composition of antibodies (summarized in Fig. 6). We advocate for additional research to explore the underlying mechanisms in maternal gut and breast tissue affected by obesity, as well as to understand the ramifications for

neonatal intestinal maturation, including the establishment of gut microbiota andmaturation of the intestine in suckling infants.

399

400 **References**

- 401 1. Shen, Z.-H. *et al.* Relationship between intestinal microbiota and ulcerative colitis:
- 402 Mechanisms and clinical application of probiotics and fecal microbiota transplantation. WJG
- **24**, 5–14 (2018).
- 404 2. Lyu, M. *et al.* ILC3s select microbiota-specific regulatory T cells to establish tolerance in the
- 405 gut. *Nature* **610**, 744–751 (2022).
- 406 3. Ramanan, D. *et al.* An Immunologic Mode of Multigenerational Transmission Governs a Gut
- 407 Treg Setpoint. *Cell* **181**, 1276-1290.e13 (2020).
- 408 4. Brodin, P. Immune-microbe interactions early in life: A determinant of health and disease long
- 409 term. *Science* **376**, 945–950 (2022).
- 410 5. Gámez-Valdez, J. S. *et al.* Differential analysis of the bacterial community in colostrum samples
- 411 from women with gestational diabetes mellitus and obesity. *Sci Rep* **11**, 24373 (2021).
- 412 6. Azad, M. B. et al. 'Human Milk Oligosaccharide Concentrations Are Associated with Multiple
- 413 Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices.
- 414 The Journal of Nutrition **148**, 1733–1742 (2018).
- 415 7. Ellsworth, L. *et al.* Impact of maternal overweight and obesity on milk composition and infant
- 416 growth. *Matern Child Nutr* **16**, (2020).
- 417 8. Daniel, A. I. *et al.* Maternal BMI is positively associated with human milk fat: a systematic
- 418 review and meta-regression analysis. The American Journal of Clinical Nutrition 113, 1009–

419 1022 (2021).

420 9. Collado, M. C., Laitinen, K., Salminen, S. & Isolauri, E. Ma	/laternal weight and excessive weigh
---	--------------------------------------

421 gain during pregnancy modify the immunomodulatory potential of breast milk. *Pediatr Res* 72,

422 77–85 (2012).

- 423 10. Fujimori, M. et al. Cytokine and adipokine are biofactors can act in blood and colostrum of
- 424 obese mothers: Cytokine and adipokine in maternal obesity. *BioFactors* **43**, 243–250 (2017).
- 425 11. Leghi, G. et al. The Impact of Maternal Obesity on Human Milk Macronutrient Composition: A
- 426 Systematic Review and Meta-Analysis. *Nutrients* **12**, 934 (2020).
- 427 12. Erliana, U. D. & Fly, A. D. The Function and Alteration of Immunological Properties in Human
- 428 Milk of Obese Mothers. *Nutrients* **11**, 1284 (2019).
- 429 13. Piñeiro-Salvador, R. et al. A cross-sectional study evidences regulations of leukocytes in the
- 430 colostrum of mothers with obesity. *BMC Med* **20**, 388 (2022).
- 431 14. Colonna-Romano, G. et al. A double-negative (lgD–CD27–) B cell population is increased in the
- 432 peripheral blood of elderly people. *Mechanisms of Ageing and Development* **130**, 681–690
- 433 (2009).
- 434 15. Frasca, D., Diaz, A., Romero, M. & Blomberg, B. B. Phenotypic and Functional Characterization
- 435 of Double Negative B Cells in the Blood of Individuals With Obesity. Front. Immunol. 12,
- 436 616650 (2021).
- 437 16. Brouwer, S. *et al.* Pathogenesis, epidemiology and control of Group A Streptococcus infection.
- 438 *Nat Rev Microbiol* **21**, 431–447 (2023).
- 439 17. Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B. & Seed, B. CD44 is the principal cell
- surface receptor for hyaluronate. *Cell* **61**, 1303–1313 (1990).
- 18. Cywes, C. & Wessels, M. R. Group A Streptococcus tissue invasion by CD44-mediated cell
- 442 signalling. *Nature* **414**, 648–652 (2001).

- 443 19. Trend, S. et al. Leukocyte Populations in Human Preterm and Term Breast Milk Identified by
- 444 Multicolour Flow Cytometry. *PLoS ONE* **10**, e0135580 (2015).
- 445 20. Whyte, C. E., Tumes, D. J., Liston, A. & Burton, O. T. Do more with Less: Improving High
- 446 Parameter Cytometry Through Overnight Staining. *Current Protocols* **2**, (2022).
- 447 21. Cervantes-Díaz, R. et al. Circulating B10 regulatory cells are decreased in severe and critical
- 448 COVID-19. Journal of Leukocyte Biology **112**, 333–337 (2022).
- 449 22. Sosa-Hernández, V. A. et al. B Cell Subsets as Severity-Associated Signatures in COVID-19
- 450 Patients. Front. Immunol. **11**, 611004 (2020).
- 451 23. Qognit. https://legendplex.qognit.com/user/login?next=home.
- 452 24. Appelgren, D. et al. Regulatory B cells are reduced in the blood in patients with
- 453 granulomatosis with polyangiitis, and fail to regulate T-cell IFN-γ production. *Clin Exp Immunol*
- **213**, 190–201 (2023).
- 455 25. Zaimoku, Y. et al. Deficit of circulating CD19+CD24hiCD38hi regulatory B cells in severe
- 456 aplastic anaemia. *Br J Haematol* **190**, 610–617 (2020).
- 457 26. Lima, J. et al. Characterization of B cells in healthy pregnant women from late pregnancy to
- 458 post-partum: a prospective observational study. BMC Pregnancy and Childbirth 16, 139
- 459 (2016).
- 460 27. Peroni, D. G. et al. Colostrum-derived B and T cells as an extra-lymphoid compartment of
- 461 effector cell populations in humans. *The Journal of Maternal-Fetal & Neonatal Medicine* **26**,
- 462 137–142 (2013).
- 463 28. Tuaillon, E. et al. Human Milk-Derived B Cells: A Highly Activated Switched Memory Cell
- 464 Population Primed to Secrete Antibodies. *J Immunol* **182**, 7155–7162 (2009).
- 465 29. Winer, D. A. *et al.* B cells promote insulin resistance through modulation of T cells and
- 466 production of pathogenic IgG antibodies. *Nat Med* **17**, 610–617 (2011).

- 467 30. O'Rourke, R. W. et al. Depot-specific differences in inflammatory mediators and a role for NK
- 468 cells and IFN-gamma in inflammation in human adipose tissue. *Int J Obes (Lond)* 33, 978–990
 469 (2009).
- 470 31. Tedder, T. F. B10 Cells: A Functionally Defined Regulatory B Cell Subset. The Journal of
- 471 *Immunology* **194**, 1395–1401 (2015).
- 472 32. Nishimura, S. et al. Adipose Natural Regulatory B Cells Negatively Control Adipose Tissue
- 473 Inflammation. *Cell Metabolism* **18**, 759–766 (2013).
- 474 33. Ellulu, M. S., Patimah, I., Khaza'ai, H., Rahmat, A. & Abed, Y. Obesity and inflammation: the
- 475 linking mechanism and the complications. *aoms* **4**, 851–863 (2017).
- 476 34. Rohm, T. V., Meier, D. T., Olefsky, J. M. & Donath, M. Y. Inflammation in obesity, diabetes, and
- 477 related disorders. *Immunity* **55**, 31–55 (2022).
- 478 35. Strom, A. et al. B regulatory cells are increased in hypercholesterolaemic mice and protect

479 from lesion development via IL-10. *Thromb Haemost* **114**, 835–847 (2015).

- 480 36. Mercadante, A. C. T. et al. Oral combined therapy with probiotics and alloantigen induces B
- 481 cell-dependent long-lasting specific tolerance. J Immunol 192, 1928–1937 (2014).
- 482 37. Rosser, E. C. et al. Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-
- 483 Hydrocarbon Receptor Activation in Regulatory B Cells. Cell Metabolism 31, 837-851.e10
- 484 (2020).
- 485 38. Rosser, E. C. *et al.* Regulatory B cells are induced by gut microbiota–driven interleukin-1β and
- 486 interleukin-6 production. *Nat Med* **20**, 1334–1339 (2014).
- 487 39. Machann, J. et al. Age and gender related effects on adipose tissue compartments of subjects
- 488 with increased risk for type 2 diabetes: a whole body MRI / MRS study. *MAGMA* **18**, 128–137
- 489 (2005).

- 490 40. Jenks, S. A. *et al.* Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7
- 491 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. *Immunity* **49**, 725-
- 492 739.e6 (2018).
- 493 41. Woodruff, M. C. et al. Extrafollicular B cell responses correlate with neutralizing antibodies
- 494 and morbidity in COVID-19. *Nat Immunol* **21**, 1506–1516 (2020).
- 495 42. Stewart, A. et al. Single-Cell Transcriptomic Analyses Define Distinct Peripheral B Cell Subsets
- 496 and Discrete Development Pathways. *Front. Immunol.* **12**, 602539 (2021).
- 497 43. Winer, D. A., Winer, S., Chng, M. H. Y., Shen, L. & Engleman, E. G. B Lymphocytes in obesity-
- related adipose tissue inflammation and insulin resistance. *Cell. Mol. Life Sci.* **71**, 1033–1043
- 499 (2014).
- 44. Scharer, C. D. *et al.* Epigenetic programming underpins B cell dysfunction in human SLE. *Nat*
- 501 *Immunol* **20**, 1071–1082 (2019).
- 45. Stone, S. L. *et al.* T-bet transcription factor promotes antibody secreting cell differentiation by
- 503 limiting the inflammatory effects of IFNγ on B cells. *Immunity* **50**, 1172-1187.e7 (2019).
- 504 46. Zumaquero, E. et al. IFNγ induces epigenetic programming of human T-bethi B cells and
- 505 promotes TLR7/8 and IL-21 induced differentiation. *eLife* **8**, e41641 (2019).
- 47. Peng, S. L., Szabo, S. J. & Glimcher, L. H. T-bet regulates IgG class switching and pathogenic
- autoantibody production. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 5545–5550 (2002).
- 48. Crouch, M., Al-Shaer, A. & Shaikh, S. R. Hormonal Dysregulation and Unbalanced Specialized
- 509 Pro-Resolving Mediator Biosynthesis Contribute toward Impaired B Cell Outcomes in Obesity.
- 510 Mol. Nutr. Food Res. 65, 1900924 (2021).
- 49. Muskiet, F., Carrera-Bastos, P., Pruimboom, L., Lucia, A. & Furman, D. Obesity and Leptin
- 512 Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for
- 513 Severe COVID-19. *Nutrients* **14**, 1388 (2022).

- 514 50. Sanz, I. et al. Challenges and Opportunities for Consistent Classification of Human B Cell and
- 515 Plasma Cell Populations. Front. Immunol. 10, 2458 (2019).
- 516 51. Arumugakani, G. et al. Early Emergence of CD19-Negative Human Antibody-Secreting Cells at
- 517 the Plasmablast to Plasma Cell Transition. *The Journal of Immunology* **198**, 4618–4628 (2017).
- 518 52. Pullen, K. M. *et al.* Selective functional antibody transfer into the breastmilk after SARS-CoV-2
- 519 infection. *Cell Reports* **37**, 109959 (2021).
- 520 53. Pabst, O. & Slack, E. IgA and the intestinal microbiota: the importance of being specific.
- 521 *Mucosal Immunol* **13**, 12–21 (2020).
- 522 54. Koch, M. A. et al. Maternal IgG and IgA Antibodies Dampen Mucosal T Helper Cell Responses
- 523 in Early Life. *Cell* **165**, 827–841 (2016).
- 524 55. van Dam, A. D. *et al.* IgG is elevated in obese white adipose tissue but does not induce glucose
- 525 intolerance via Fcγ-receptor or complement. *Int J Obes (Lond)* **42**, 260–269 (2018).
- 526 56. Frasca, D., Diaz, A., Romero, M., Thaller, S. & Blomberg, B. B. Secretion of autoimmune
- 527 antibodies in the human subcutaneous adipose tissue. *PLoS One* **13**, e0197472 (2018).
- 528 57. Petrus, P. et al. Glutamine Links Obesity to Inflammation in Human White Adipose Tissue. Cell
- 529 *Metabolism* **31**, 375-390.e11 (2020).
- 530 58. Romo, M. et al. Small fragments of hyaluronan are increased in individuals with obesity and
- 531 contribute to low-grade inflammation through TLR-mediated activation of innate immune
- cells. Int J Obes 46, 1960–1969 (2022).
- 533 59. Sherwood, E. *et al.* Invasive group A streptococcal disease in pregnant women and young
- children: a systematic review and meta-analysis. *The Lancet Infectious Diseases* 22, 1076–1088
 (2022).
- ()
- 536 60. Elsner, R. A. & Shlomchik, M. J. Germinal Center and Extrafollicular B Cell Responses in
- 537 Vaccination, Immunity, and Autoimmunity. *Immunity* **53**, 1136–1150 (2020).

- 538 61. Emami, C. N., Mittal, R., Wang, L., Ford, H. R. & Prasadarao, N. V. Role of Neutrophils and
- 539 Macrophages in the Pathogenesis of Necrotizing Enterocolitis Caused by Cronobacter
- 540 sakazakii. Journal of Surgical Research **172**, 18–28 (2012).
- 541 62. Shaw, T. N. et al. Tissue-resident macrophages in the intestine are long lived and defined by
- 542 Tim-4 and CD4 expression. *J Exp Med* **215**, 1507–1518 (2018).
- 543 63. Weber, B., Saurer, L., Schenk, M., Dickgreber, N. & Mueller, C. CX3CR1 defines functionally
- 544 distinct intestinal mononuclear phagocyte subsets which maintain their respective functions
- 545 during homeostatic and inflammatory conditions. *Eur J Immunol* **41**, 773–779 (2011).
- 546 64. Smith, P. D. et al. Intestinal macrophages lack CD14 and CD89 and consequently are down-
- regulated for LPS- and IgA-mediated activities. *J Immunol* **167**, 2651–2656 (2001).
- 548 65. Rivollier, A., He, J., Kole, A., Valatas, V. & Kelsall, B. L. Inflammation switches the
- 549 differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to
- inflammatory dendritic cells in the colon. *J Exp Med* **209**, 139–155 (2012).
- 551 66. Smythies, L. E. *et al.* Human intestinal macrophages display profound inflammatory anergy
- despite avid phagocytic and bacteriocidal activity. *J Clin Invest* **115**, 66–75 (2005).
- 553 67. Halpern, M. D. *et al.* Reduction of experimental necrotizing enterocolitis with anti-TNF-α.
- 554 *American Journal of Physiology-Gastrointestinal and Liver Physiology* **290**, G757–G764 (2006).
- 555 68. Sims, G. P. *et al.* Identification and characterization of circulating human transitional B cells.
- 556 *Blood* **105**, 4390–4398 (2005).
- 557 69. Suryani, S. et al. Differential expression of CD21 identifies developmentally and functionally
- distinct subsets of human transitional B cells. *Blood* **115**, 519–529 (2010).
- 559 70. Palanichamy, A. *et al.* Novel Human Transitional B Cell Populations Revealed by B Cell
- 560 Depletion Therapy1. *The Journal of Immunology* **182**, 5982–5993 (2009).

- 561 71. Quách, T. D. et al. Anergic Responses Characterize a Large Fraction of Human Autoreactive
- 562 Naive B Cells Expressing Low Levels of Surface IgM. The Journal of Immunology 186, 4640–
- 563 4648 (2011).
- 564 72. Golinski, M.-L. et al. CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody
- 565 Secreting Cells in Healthy Donors. *Frontiers in Immunology* **11**, (2020).
- 566 73. Jenks, S. A., Cashman, K. S., Woodruff, M. C., Lee, F. E.-H. & Sanz, I. Extrafollicular responses in
- humans and SLE. *Immunological Reviews* **288**, 136–148 (2019).
- 568 74. Shapiro-Shelef, M. et al. Blimp-1 Is Required for the Formation of Immunoglobulin Secreting
- 569 Plasma Cells and Pre-Plasma Memory B Cells. *Immunity* **19**, 607–620 (2003).
- 570 75. Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-
- 571 secreting plasma cells. *Nat Rev Immunol* **15**, 160–171 (2015).
- 572 76. Bagnara, D. et al. A Reassessment of IgM Memory Subsets in Humans. The Journal of
- 573 *Immunology* **195**, 3716–3724 (2015).
- 574 77. Grimsholm, O. CD27 on human memory B cells–more than just a surface marker. *Clinical and*
- 575 *Experimental Immunology* **213**, 164–172 (2023).
- 576 78. Saunders, S. P., Ma, E. G. M., Aranda, C. J. & Curotto de Lafaille, M. A. Non-classical B Cell
- 577 Memory of Allergic IgE Responses. *Frontiers in Immunology* **10**, (2019).
- 578 79. Sutton, H. J. *et al.* Atypical B cells are part of an alternative lineage of B cells that participates
- 579 in responses to vaccination and infection in humans. *Cell Reports* **34**, 108684 (2021).
- 580 80. Wang, S. et al. IL-21 drives expansion and plasma cell differentiation of autoreactive
- 581 CD11chiT-bet+ B cells in SLE. *Nat Commun* **9**, 1758 (2018).
- 582 81. CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are
- 583 Functionally Impaired in Systemic Lupus Erythematosus Patients: Immunity.
- 584 https://www.cell.com/immunity/fulltext/S1074-7613(09)00547-

- 585 0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS10747613090
- 586 05470%3Fshowall%3Dtrue.
- 587 82. Mauri, C. & Menon, M. Human regulatory B cells in health and disease: therapeutic potential.
- 588 J Clin Invest **127**, 772–779 (2017).
- 589

590 AUTHOR CONTRIBUTIONS

All authors approved the final version of the manuscript. ESS designed and performed experiments, analyzed data and wrote, edited, and reviewed the manuscript. DBR performed experiments, analyzed data and reviewed the manuscript. MRAG, VJLD and CNLV, designed experiments, enrolled participants, collected samples, edited, and reviewed the manuscript. MEGB designed the study, analyzed data, wrote, edited, and reviewed the manuscript.

597

598 DECLARATION OF COMPETING INTEREST

599 The authors declare no conflict of interest.

600

601 **FUNDING**

This research was supported by the Institute for Obesity Research and the Centro de Biotecnología FEMSA of Tecnológico de Monterrey, and sponsored by StrainBiotech SAPI de CV.

605

606 DATA AVAILABILITY

All .fcs3 files obtained as part of this work will be made freely available onFlowRepository upon paper acceptance (in process)

609

610 **ACKNOWLEDGEMENTS**

611 We acknowledge institutional support in all administrative processes involved with

a clinical study. We are deeply grateful to participating families.

613

614 Table 1: Participants characteristics

	Group				
Variable	Le	ean, n = 23	Ob	ese, n = 25	P value
Maternal age (years) ^a	21	(20 - 24)	23.5	(20 -27.5)	0.099
BMI (kg/m²) ^a	21.4	(18.7 - 24.1)	30.3	(30.0 - 31.9)	<0.0001
Body fat percentage (%) ^a	20	(15 - 22)	39.1	(34 - 42)	<0.0001
Gestational age (weeks) ^a	38	(37 - 39)	38	(37 - 39)	0.690
Primiparity ^a	2	(1 - 3)	3	(1.75 - 4)	0.104
Vaginal delivery ^b	23	(100)	24	(92.3)	0.491
Newborn female gender ^b	9	(39.1)	15	(60)	0.156
Newborn male gender ^b	14	(60.9)	10	(40)	
Birth weight (g) ^a	3070	(2700 - 3290)	3000	(2742 - 3255)	0.411
Birth height (cm) ^a	49	(47 - 50)	49	(47 - 50)	0.832

615

Notes: BMI = Body Mass Index; a = Values expressed as median (IQR), statistical

analysis with Independent-Samples Median test, b = Values expresses as

618 frequency (%), statistical analysis with Fisher's exact test.

619

Table 2: Flow cytometry-based identification of B lymphocyte subtypes

B cell subpopulation (acronym)	Surface markers phenotype	References
Total B cells (B cells)	CD19⁺	27
Transitional B cells type 1 (T1)	CD19 ⁺ , CD27 ⁻ , CD38 ^{hi} , CD24 ^{hi} , CD21 ^{neg/low}	68,69
Transitional B cells type 2 (T2)	CD19 ⁺ , CD27 ⁻ , CD38 ^{hi} , CD24 ^{hi} , CD21 ⁺	69,70
Resting naïve B cells (resN)	CD19 ⁺ , CD27 ⁻ , IgD ⁺ , CD38 ⁺ , CD24 ⁻ , CD11c ⁻	71,72

Active naïve B cells (actN)	CD19 ⁺ , CD27 ⁻ , IgD ⁺ , CD38 ⁺ ,	72,73
	CD24 ⁻ , CD11c ⁺	
Total plasma-like cells (Plasma-	CD19 ⁺ , CD27 ^{hi} , CD38 ^{hi}	74,75
like cells)		
Plasma-like cells expressing IgA	CD19 ⁺ , CD27 ^{hi} , CD38 ^{hi} , IgA ⁺	
(IgA⁺ plasma-like cells)		
Plasma-like cells expressing IgG	CD19 ⁺ , CD27 ^{hi} , CD38 ^{hi} , IgG ⁺	
(IgG⁺ plasma-like cells)		
Unswitched memory B cells	CD19 ⁺ , CD27 ⁺ , IgD ⁺	76,77
(USwM)		
IgG switched memory (IgG ⁺	CD19 ⁺ , CD27 ⁺ , IgD ⁻ , IgG ⁺	
SwM)		
IgA switched memory (IgA ⁺	CD19 ⁺ , CD27 ⁺ , IgD ⁻ , IgA ⁺	
SwM)		
Unswitched non-classical	CD19 ⁺ , CD38 ^{neg/low} , CD24 ⁺ ,	78,79
memory (M CD27⁻ IgD ⁺)	CD27 ⁻ , IgD ⁺	
Switched non-classical memory	CD19 ⁺ , CD38 ^{neg/low} , CD24 ⁺ ,	
or (M CD27⁻ IgD ⁻)	CD27 ⁻ , IgD ⁻	
Double negative B cell subtype 1	CD19 ⁺ , CD27 ⁻ , IgD ⁻ , CD38 ^{-/+} ,	40,80
(DN1-like)	CD24 ⁻ , CD21 ⁺ , CD11c ⁻	
Double negative B cell subtype 2	CD19 ⁺ , CD27 ⁻ , IgD ⁻ , CD38 ⁻ ,	
(DN2-like)	CD24 ⁻ , CD21 ⁻ , CD11c ⁺	
Double negative B cell subtype 3	CD19 ⁺ , CD27 ⁻ , IgD ⁻ , CD38 ^{-/+} ,	
(DN3-like)	CD24 ⁻ , CD21 ⁻ , CD11c ⁻	
Double negative B cell subtype 4	CD19 ⁺ , CD27 ⁻ , IgD ⁻ , CD38 ⁻ ,	
(DN4-like)	CD24 ⁻ , CD21 ⁺ , CD11c ⁺	
B reg-like cells (Breg-like cells)	CD19 ⁺ , CD38 ⁺ , CD24 ⁺	81,82

621

622 FIGURE LEGENDS

623

Fig. 1: Human colostrum and peripheral blood are differentially enriched in 624 625 multiple B lymphocyte subtypes. a) Concentrations of transitional and naïve B cells in peripheral blood and colostrum. b) Concentrations of B_{rea}-like, DN2-like and 626 plasma-like cells in peripheral blood and colostrum. c) Concentrations of USwM 627 and SwM in blood and colostrum (above) and subsampling comparing samples 628 from mothers with BMI<25 ("lean") and mothers with BMI>30 ("obese") (below). 629 Statistical analysis was performed using Mann-Whitney U tests, comparing B cell 630 subsets concentrations (live cells/ml or original blood or colostrum) from mothers 631 with obesity (n=25) or with a lean BMI (n=23). *p < 0.05, **p< 0.01, ***p < 0.001 632 and ****p < 0.0001. 633

634

Fig. 2: Maternal BMI and BF% correlates with the frequency of Breg-like, 635 double-negative (DN2) and plasma-like cells in colostrum. Comparisons of a) 636 B_{rea}-like, **b**) DN2-like and **c**) plasma-like cell % in colostrum from lean and obese 637 638 cohorts (left of the 3 panels), and correlations with between pre-pregnancy BMI values (middle) and BF% (right). Doted lines represent SE. Mann-Whitney U tests 639 640 were used to compare B cell subsets in colostrum from both cohorts. Pearson correlations were used to investigate the relationships between B cell subsets % 641 642 and BMI or BF%. **p < 0.01 and ****p < 0.0001.

643

644 Fig. 3: IgG production is increased in colostrum from mothers with obesity. a) Relative contribution of IgA⁺ and IgG⁺ plasma-like cells between cohorts (mean 645 646 ± SD). Comparisons performed using Mann-Whitney U test **p<0.01. b) Intraindividual correlation analysis of IgA⁺ and IgG⁺ colostrum plasma-like cells in both 647 groups. Spearman tests compared Z-Scores of IgA⁺ and IgG⁺ plasma-like cells 648 proportions. c) Comparison of IgG and IgA-secreting colostrum cells in both 649 cohorts (left), and Pearson correlations with maternal BMI (middle) and BF% 650 (right). d) Concentration of total IgG (mg/ml) and GlcNAc-specific IgG (ng/ml) 651 (above) and total IgA (mg/ml) in both groups (individual data, with mean ± SD). 652 Comparisons performed through Mann-Whitney U test *p < 0.05, **p<0.01, ****p < 653 0.0001. 654

Fig. 4: IgG⁺-DN2 cells and IgG⁺-plasma like cells contribute to local IgG
production in obesity. a) Representative colostrum DN2-like B cells plot showing
IgA or IgG expression. b) Correlations between IgG⁺ plasma-like cells and DN2like cell proportions with IgG concentrations in lean (red) and obese (gray) cohorts.
Correlations between IgG⁺ plasma-like cells and DN2-like cell proportions with
concentrations of IgG-secreting cells in lean (red) and obese (gray) cohorts.
Trends were compared by Spearman rank.

663

Fig. 5: Obese colostrum prompts cytokines production by human macrophages. Supernatant concentrations of a) TNF-α and b) IL-6 produced over a 16h period by human macrophages (black), human macrophages incubated for 24 h with filtered colostrum supernatant from the lean cohort (gray) or obese cohort (red). Each timepoint represents the mean of three biological replicates ±SD. Comparisons with two-way ANOVA and Turkey's post-hoc test. *p < 0.05, **p<0.01, ***p<0.001 and ****p < 0.0001.

671

Fig. 6: Overview of obesity-related alterations in B lymphocyte subtypes in 672 673 maternal peripheral blood and colostrum. Transitional B cells (1) differentiate into B_{reg} cells (2) and migrate from the blood into the lactating duct (2a). 674 675 Transitional B cells (1) also migrate to secondary tissues. There, transitional B cells differentiate into naïve B cells (3) and enter germinal centers (3a) or are activated 676 677 through the extrafollicular pathway to differentiate into DN2-like B cells (4). These (4) could migrate to multiple tissues, including the lactating mammary gland and 678 colostrum (4a), where they are increased in obesity. Here we provide evidence that 679 DN2-like B cells could differentiate into IgG⁺ plasma-like cells (6a) and IgG-680 secreting cells (7a) to increase IgG produced in obesity (8). In the germinal center, 681 naïve B cells (3), after germinal center reaction (3a) and can differentiate into two 682 subpopulations: (5) memory B cells or (6) plasma-like cells. Memory B cells 683 migrate through blood to mammary acini and colostrum (5a). We have shown that 684 in obesity, colostrum USwM cells are decreased. Finally, colostrum IgG-secreting 685

⁶⁵⁵

cells and sIgG increase in obesity (7a) while colostrum IgA-secreting cells and sIgA
 are reduced (8). Created with BioRender.com

688

Supplementary Fig. 1: Gating strategy used for manual gating of B cells subsets in colostrum. Transitional B cells in brown, naïve B cells in yellow, regulatory B cells in green, memory B cells in orange, plasma-like cells in red, and double-negative B cell subsets (DN1, DN2, DN3 and DN4) in blue. Dot plots are represented in Contour plots, at least at 5% of level and included outliers in FlowJo X® version Software, BD Biosciences.

695

Supplementary Fig. 2: CD19⁺ B cells are decreased in the colostrum from
mothers with obesity a) Total CD19⁺ B cells in blood and in colostrum from both
cohorts. Groups compared using Mann-Whitney U test. ***p < 0.001.

699

700 Supplementary Fig. 3: Human colostrum contains percentages of subpopulations of differentiated B cells enriching in comparison with blood. 701 702 a) Scatter plots comparing transitional and naïve B cells in blood and colostrum. b) Scatter plots comparing regulatory B cells (Breg-like), double negative 2 (DN2-like) 703 704 and plasma-like cells in blood and in colostrum. c) Scatter plots comparing unswitched memory (USwM) and switched memory B cells (SwM) in blood and 705 706 colostrum (above). Scatter plots comparing USwM and SwM in colostrum from lean and mothers with obesity (below). Statistical analysis was performed using the 707 708 Mann-Whitney U test, comparing B cell subsets percentages in blood from mothers with obesity (n=25) against lean subjects as control (n=23). *p < 0.05, **p< 0.01, 709 ***p < 0.001 and ****p < 0.0001. 710

711

Supplementary Fig. 4. Obesity induces differentiation of plasma-like cells on
CD19 low expression group. a,b) Examples of histograms from plasma-like cells
analyzed in function of CD19 expression, showing negative CD19 population (left)
and positive CD19 expression groups (right), from colostrum of lean and mothers.
Column bar graph comparing plasma-like cells in function of percentage of (% of

CD19⁺) low (no pattern), median (square pattern), and high (line pattern) CD19 expression groups. Bars indicate the mean \pm SD. Statistical analysis was performed using the Kruskal Wallis test for multiple comparisons (Lean n=23 and obesity n=25) assay. ***p<0.001.

Fig. 1















Lean







Obese













Fig. 4







Fig. 5



Co-incubation with obese colostrum supernatant













Plasma-like cells (CD19⁺ CD27^{hi} CD38^{hi})

